ESR1 and breast cancer: Our previous study also detected the requirement of MAP2K7 for the fulvestrant-induced MCF-7 cell death.46 Furthermore, Iorns et al.25 demonstrated the requirement of MAP2K7 for inhibition of MCF-7 cell proliferation by tamoxifen, another antiestrogen drug prescribed for ERα-positive breast cancers.